Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

Core Insights - Femasys Inc. will showcase its innovative fertility solutions at the ASRM 2025 Scientific Congress & Expo in San Antonio, Texas from October 25-29 [1][4] - The company is highlighting its next-generation artificial insemination solution, FemaSeed, which has demonstrated more than double the pregnancy rates of traditional intrauterine insemination (IUI) in cases of low male sperm count [2][5] - Femasys has expanded its FemaSeed portfolio to include various kits that enable gynecologists to perform sperm preparation and offer FemaSeed directly in their practices [3] Company Overview - Femasys is a biomedical innovator focused on making fertility and non-surgical permanent birth control more accessible and cost-effective for women globally [5] - The company has a patent-protected portfolio of therapeutic and diagnostic products, including FemaSeed and FemVue, aimed at improving reproductive health [5] - Femasys has received regulatory approvals for its products in multiple regions, including the U.S., Europe, UK, Canada, Israel, Australia, and New Zealand [2][6] Product Highlights - FemaSeed is positioned as a safe, accessible, and cost-effective alternative to IUI, particularly for patients with low male sperm count [2] - The FemBloc product, a non-surgical permanent birth control solution, received full regulatory approval in Europe, the UK, and New Zealand in 2025 [6] - The FemChec diagnostic product provides an ultrasound-based test to confirm procedural success for FemBloc [6]